Page 169 - Genentech News Today

WEDNESDAY, April 26, 2023 (HealthDay News) -- Unawareness, rather than heightened awareness, of memory decline is strongly associated with future clinical progression in older adults, according to a study published online April 25 in JAMA Network Open. Kayden J. Mimmack, from the Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues investigated the

Bristol Myers Squibb’s leadership team is set to reshuffle, with Christopher Boerner becoming it’s new CEO in late 2023.

More than 90% of Black and Hispanic MS patients experienced no new relapses or disability worsening after one year of Ocrevus treatment.

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect

Over 2 years of treatment with tolebrutinib was safe and kept relapse rates low for multiple sclerosis patients in a Phase 2 trial extension.

WEDNESDAY, April 26, 2023 (HealthDay News) -- Unawareness, rather than heightened awareness, of memory decline is strongly associated with future clinical progression in older adults, according to a study published

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the American Academic of Neurology annual meeting. Stephen P. Salloway, MD, MS, the Martin M. Zucker Professor of Psychiatry and Human Behavior and professor of neurology at Brown University